CRKL Human siRNA Oligo Duplex (Locus ID 1399)
CAT#: SR300987
CRKL (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each
Need single siRNA in bulk?
Get a free quote
CNY 4,090.00
货期*
4周
规格
Cited in 2 publications. |
Product images
经常一起买 (3)
Specifications
Product Data | |
Purity | HPLC purified |
Quality Control | Tested by ESI-MS |
Sequences | Available with shipment |
Stability | One year from date of shipment when stored at -20°C. |
# of transfections | Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM). |
Note | Single siRNA duplex (10nmol) can be ordered. |
Reference Data | |
RefSeq | NM_005207, NR_156180 |
Components | CRKL (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 1399)Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmolIncluded - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml |
Summary | This gene encodes a protein kinase containing SH2 and SH3 (src homology) domains which has been shown to activate the RAS and JUN kinase signaling pathways and transform fibroblasts in a RAS-dependent fashion. It is a substrate of the BCR-ABL tyrosine kinase, plays a role in fibroblast transformation by BCR-ABL, and may be oncogenic.[provided by RefSeq, Jan 2009] |
Performance Guranteed | OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency. For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required). |
Citations (2)
The use of this RNAi has been cited in the following citations: |
---|
Copy number gains of the putative CRKL oncogene in laryngeal squamous cell carcinoma result in strong nuclear expression of the protein and influence cell proliferation and migration
,Kostrzewska-Poczekaj, M;Bednarek, K;Jarmuz-Szymczak, M;Bodnar, M;Filas, V;Marszalek, A;Bartochowska, A;Grenman, R;Kiwerska, K;Szyfter, K;Giefing, M;,
Sci Rep
,PubMed ID 31913340
[CRKL]
|
Escherichia coli virulence protein NleH1 interaction with the v-crk sarcoma virus CT10 oncogene-Like protein (CRKL) governs NleH1 inhibition of the ribosomal protein S3 (RPS3)/NF-kappaB pathway
,Pham, TH;Gao, X;Singh, G;Hardwidge, PR;,
J Biol Chem. 2013 Oct 21
,PubMed ID 24145029
[CRKL]
|
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...